CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Danazoldrug
Likely dose
Danazol 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01441037
NCT01441037Phase 2Completed

Male Hormones for Telomere Related Diseases

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Sep 27, 2011·Updated Aug 15, 2018

In Brief

A Phase 2 clinical trial evaluating Danazol for Aplastic Anemia. Completed, enrolled 27 participants across 1 site.

Detailed Summary

Background: \- Some people have bone marrow and lung disorders that are caused by genetic problems. These problems often involve damage to the ends of the chromosomes that pass down genes. One of these disorders is aplastic anemia. This is a disorder in which the bone marrow does not make enough blood cells. Currently, doctors use a male hormone-based drug called Danazol to improve bone marrow function and treat aplastic anemia. More information is needed on whether Danazol can help repair the damaged chromosomes that cause aplastic anemia and similar disorders that cause low blood cell counts or lung problems. Objectives: \- To study the safety and effectiveness of Danazol for bone marrow and lung disorders caused by damaged genes. Eligibility: \- Individuals at least 2 years of age who have low blood cell counts or lung fibrosis caused by damaged genes. Design: * Participants will be screened with a physical exam and medical history. Then they will have blood and urine tests, imaging studies, and a lung function test. They will also take a 6-minute walking test and have a bone marrow biopsy. * Participants will receive Danazol to take twice a day for the duration of the study. * Participants will have regular study visits at 6, 12, and 24 months, with blood tests, imaging studies, a lung function test, and a 6-minute walking test. A bone marrow sample will be collected at the 12-month visit. * Participants will remain on the study for up to 2 years. Researchers will follow up with them for 2 years after the end of the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAplastic Anemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 27, 2011
Enrollment StartJul 19, 2011
Primary CompletionNov 14, 2016
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 14.8 years ago

Interventions

Danazoldrug

Danazol, 800 mg daily by mouth for 2 years